You are here

Vigabatrin Approved for Adult and Pediatric Epileptic Seizures

Adjunctive Therapy is First Generic Version of Sabril for Focal Seizures

The FDA has approved vigabatrin 500 mg tablets (Teva Pharmaceuticals USA) as an adjunctive therapy for complex partial seizures. The drug is indicated for treating focal seizures in patients aged 10 years and older who have responded inadequately to several alternative treatments.

Complex partial seizures begin in a specific part of the brain and can affect consciousness. They typically last between 30 and 90 seconds, and are often followed by disorientation, confusion, and/or fatigue.

Vigabatrin’s most common side effects include dizziness, fatigue, somnolence, involuntary eye movement, tremor, blurred vision, memory impairment, weight gain, arthralgia, upper respiratory tract infection, aggression, diplopia, abnormal coordination, and a confused state. Serious side effects include permanent vision loss and risk of suicidal thoughts or actions.

Source: PR Newswire, January 16, 2019

Recent Headlines

Medical Device Enables Nerve Stimulation During Sleep
May Offer Improved Safety Profile for Pediatric Patients
Hope for Sufferers With Post-Treatment Lyme Disease Syndrome
KardiaMobile Receives Two More Clearances for Arrhythmia Detection
Antibiotics, Statins, and Glucocorticoids All Show Promise
Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Current, Sole Therapy Not Always Successful/Suitable